The federal government will review whether the Food and Drug Administration properly inspected the Abbott Laboratories baby formula plant in Michigan whose closure over unsanitary conditions caused a nationwide shortage that left the Biden administration unprepared.The Department of Health and Human Services inspector general’s office will conduct the review that is expected to conclude sometime next year, the agency said in a statement Thursday. “We will review FDA’s actions leading up to the infant formula recall at the Abbott facility in February 2022 to determine whether FDA followed applicable policies and procedures to: (1) conduct inspections of the manufacturing facility and (2) oversee Abbott’s initiation of the infant formula recall,” HHS said.
Load More
Load More